ArticleApplied biochemistry and biotechnology2026
Production and Characterisation of Mobilisin, a Broad-Spectrum Antimicrobial Peptide from Bacillus mobilis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial peptides offer significant potential in addressing antimicrobial resistance, as pathogens develop low or no resistance against them. This study aimed to isolate and screen AMP-producing bacteria from environmental samples with broad-spectrum antibacterial activity. Preliminary screening yielded 185 AMP-producing bacterial isolates and subsequently, the most promising isolate with broad-spectrum antibacterial activity was identified as Bacillus mobilis by 16S rRNA sequencing. The AMP from B. mobilis was named mobilisin and purified by hydrophobic adsorption chromatography using Diaion HP-20, followed by RP-HPLC. The molecular weight and probable sequence of mobilisin were observed to be 861.16 Da and KNMFPPK, respectively, using LC-MS/MS and PEAKS Studio 11 analysis. The purified mobilisin showed a notable antibacterial spectrum against both Gram-negative and Gram-positive bacteria with MICs of 31.25 and 62.5 µg/ml, respectively. The antibacterial potential of mobilisin was further confirmed with the synthesised peptide (KNMFPPK), which showed MIC in a similar range. The purified mobilisin exhibited thermal stability at a wide temperature range (4 °C to 80 °C) and maintained its integrity over a broad pH (2.0-11.0) range. Mobilisin also exhibited stability in the presence of various surfactants and organic solvents. The bactericidal potential of mobilisin was confirmed in vitro by scanning electron microscopy (SEM), where it displayed high efficacy by destroying the cell membrane integrity of both Gram-positive and Gram-negative bacteria. The purified mobilisin further demonstrated its applicability in fresh produce preservation by inhibiting the growth of Gram-negative and Gram-positive bacteria on strawberry fruits. Given its broad-spectrum antibacterial properties and biochemical resilience, mobilisin holds the potential for diverse applications in the pharmaceutical and food sectors.
Indexed as
Identifiers
41196560What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.